ERBB2 and breast carcinoma: Organ-level and kidney micro-dosimetry estimates in rodents and primates support a proposed starting administered activity of 400 MBq of 64Cu-MM-302 for clinical imaging studies in patients with advanced HER2-positive breast cancer (NCT01304797).